ישראל - עברית - Ministry of Health

sanofi - aventis israel ltd - aflibercept 25 mg/ml - concentrate for solution for infusion - zaltrap, in combination with 5-fluorouracil, leucovorin, irinotecan (folfiri), is indicated for adults with metastatic colorectal cancer (mcrc) that is resistant to or has progressed following an oxaliplatin-containing regimen.

ישראל - עברית - Ministry of Health

sanofi israel ltd - diphtheria toxoid; filamentous haemagglutinin (fha); fimbrae tupes 2 + 3 (fim); pertactin (prn); pertussis toxoid vaccine; tetanus toxoid - תרחיף להזרקה - tetanus toxoid 5 lf / 1 doses; pertussis toxoid vaccine 2.5 mcg/dose; filamentous haemagglutinin (fha) 5 mcg/dose; fimbrae tupes 2 + 3 (fim) 5 mcg/dose; pertactin (prn) 3 mcg/dose; diphtheria toxoid 2 lf / 1 doses - diphtheria-pertussis-poliomyelitis-tetanus

ישראל - עברית - Ministry of Health

sanofi israel ltd - valproic acid; valproic acid as sodium - טבליות בשחרור ממושך - valproic acid 145 mg; valproic acid as sodium 333 mg - valproic acid

ישראל - עברית - Ministry of Health

sanofi israel ltd - diphtheria toxoid; filamentous haemagglutinin (fha); haemophilus influenzae type b polysaccharide; hepatitis b vaccines; pertussis toxoid (pt); poliovirus type 1 inactivated; poliovirus type 2 inactivated; poliovirus type 3 inactivated; tetanus protein conjugate; tetanus toxoid - תרחיף להזרקה - diphtheria toxoid; tetanus protein conjugate 22 - 36 mcg / 0.5 ml; haemophilus influenzae type b polysaccharide 12 mcg / 0.5 ml; hepatitis b vaccines 10 mcg / 0.5 ml; poliovirus type 3 inactivated 32 du / 0.5 ml; poliovirus type 2 inactivated 8 du / 0.5 ml; poliovirus type 1 inactivated 40 du / 0.5 ml; filamentous haemagglutinin (fha) 25 mcg / 0.5 ml; pertussis toxoid (pt) 25 mcg / 0.5 ml; tetanus toxoid - diphtheria-hemophilus influenzae b-pertussis-poliomyelitis-tetanus-hepatitis b

ישראל - עברית - Ministry of Health

sanofi israel ltd - a/darwin/9/2021 (h3n2)-like virus; a/victoria/4897/2022 (h1n1)pdm09-like virus; b/austria/1359417/2021 (b/victoria lineage)-like virus; b/phuket/3073/2013 (b/yamagata lineage)-like virus - תרחיף להזרקה - b/phuket/3073/2013 (b/yamagata lineage)-like virus 30 mcg ha / 1 ml; a/darwin/9/2021 (h3n2)-like virus 30 mcg ha / 1 ml; b/austria/1359417/2021 (b/victoria lineage)-like virus 30 mcg ha / 1 ml; a/victoria/4897/2022 (h1n1)pdm09-like virus 30 mcg ha / 1 ml - influenza, inactivated, split virus or surface antigen

ישראל - עברית - Ministry of Health

sanofi - aventis israel ltd - lixisenatide - תמיסה להזרקה - lixisenatide 10 mcg / 0.2 ml - lixisenatide

ישראל - עברית - Ministry of Health

sanofi israel ltd - yellow fever virus strain 17d204 (substrain ab237) - אבקה וממס להכנת תרחיף להזרקה - yellow fever virus strain 17d204 (substrain ab237) - yellow fever, live attenuated

ישראל - עברית - Ministry of Health

sanofi israel ltd - sarilumab - תמיסה להזרקה - sarilumab 131.6 mg / 1 ml - sarilumab

ישראל - עברית - Ministry of Health

sanofi israel ltd - sarilumab - תמיסה להזרקה - sarilumab 175 mg / 1 ml - sarilumab

ישראל - עברית - Ministry of Health

sanofi israel ltd - conjugated to tetanus protein; diphtheria toxoid; filamentous haemagglutinin (fha); haemophilus influenzae type b polysaccharide; pertussis toxoid (pt); polio type i (mohoney); polio type ii ( m.e.f.1); polio type iii (saukett); tetanus toxoid - אבקה ותרחיף להכנת תרחיף להזרקה - polio type iii (saukett) 32 du / 0.5 ml; polio type ii ( m.e.f.1) 8 du / 0.5 ml; polio type i (mohoney) 40 du / 0.5 ml; filamentous haemagglutinin (fha) 25 mcg / 0.5 ml; pertussis toxoid (pt) 25 mcg / 0.5 ml; tetanus toxoid 40 iu / 0.5 ml; diphtheria toxoid 30 iu / 0.5 ml; haemophilus influenzae type b polysaccharide 10 mcg / 0.5 ml; conjugated to tetanus protein 18-30 mcg / 0.5 ml - diphtheria-hemophilus influenzae b-pertussis-poliomyelitis-tetanus